Fischlein T, Folliguet T, Meuris B, et al. - In a prospective, randomized, adaptive, open-label trial (PERSIST-AVR), it was inquired if sutureless bioprostheses are noninferior to standard bioprostheses in severe symptomatic aortic stenosis. Patients were randomly assigned to aortic valve replacement (AVR) with a sutureless or stented valve using conventional or minimally invasive approach. Freedom from major adverse cerebral and cardiovascular events (MACCE; composite of all-cause mortality, myocardial infarction, stroke, or valve reintervention) at 1 year was the primary outcome. Findings demonstrated the noninferiority of sutureless valve to stented valves in terms of MACCE at 1 year in patients receiving AVR (alone or with coronary artery bypass grafting). This indicates that consideration should be given to sutureless valves as a component of a comprehensive valve program.